Enhancement of Endoplasmic Reticulum (ER) Degradation of Misfolded Null Hong Kong {alpha}1-Antitrypsin by Human ER Mannosidase I*

Nobuko Hosokawa {ddagger} § , Linda O. Tremblay ||, Zhipeng You ||, Annette Herscovics ||, Ikuo Wada § ** {ddagger}{ddagger} and Kazuhiro Nagata {ddagger} §

From the {ddagger}Department of Molecular and Cellular Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8397, Japan, §Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Saitama 332-0012, Japan, ||McGill Cancer Centre, McGill University, Montréal, Québec H3G 1Y6, Canada, and **Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan

Received for publication, April 2, 2003 , and in revised form, May 3, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Misfolded glycoproteins synthesized in the endoplasmic reticulum (ER) are degraded by cytoplasmic proteasomes, a mechanism known as ERAD (ER-associated degradation). In the present study, we demonstrate that ERAD of the misfolded genetic variant-null Hong Kong {alpha}1-antitrypsin is enhanced by overexpression of the ER processing {alpha}1,2-mannosidase (ER ManI) in HEK 293 cells, indicating the importance of ER ManI in glycoprotein quality control. We showed previously that EDEM, an enzymatically inactive mannosidase homolog, interacts with misfolded {alpha}1-antitrypsin and accelerates its degradation (Hosokawa, N., Wada, I., Hasegawa, K., Yorihuzi, T., Tremblay, L. O., Herscovics, A., and Nagata, K. (2001) EMBO Rep. 2, 415–422). Herein we demonstrate a combined effect of ER ManI and EDEM on ERAD of misfolded {alpha}1-antitrypsin. We also show that misfolded {alpha}1-antitrypsin NHK contains labeled Glc1Man9GlcNAc and Man5–9GlcNAc released by endo-{beta}-N-acetylglucosaminidase H in pulse-chase experiments with [2-3H]mannose. Overexpression of ER ManI greatly increases the formation of Man8GlcNAc, induces the formation of Glc1Man8GlcNAc and increases trimming to Man5–7GlcNAc. We propose a model whereby the misfolded glycoprotein interacts with ER ManI and with EDEM, before being recognized by downstream ERAD components. This detailed characterization of oligosaccharides associated with a misfolded glycoprotein raises the possibility that the carbohydrate recognition determinant triggering ERAD may not be restricted to Man8GlcNAc2 isomer B as previous studies have suggested.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The synthesis of glycoproteins containing N-glycans begins in the endoplasmic reticulum (ER)1 with the addition of the Glc3Man9GlcNAc2 precursor of N-linked glycans to nascent polypeptide chains. Subsequently, the ER lectin chaperones, calnexin or calreticulin, specifically bind to monoglucosylated N-glycans, promoting proper glycoprotein folding. This ER quality control process is mediated by glucosidases I and II that remove the glucose residues from Glc3Man9GlcNAc2 and by UDP-glucose:glycoprotein glucosyltransferase that reglucosylates incompletely folded glycoproteins. Correctly folded glycoproteins exit the ER to their final destinations, whereas misfolded glycoproteins are readily degraded (for reviews see Refs. 14). Many terminally misfolded proteins in the ER are degraded by cytoplasmic proteasomes, a mechanism known as ERAD (for reviews see Refs. 57). Experimental evidence in yeast and mammalian cells suggests that ER {alpha}1,2-mannosidase I (ER ManI) that primarily removes the middle branch mannose from Man9GlcNAc2 to form Man8GlcNAc2 isomer B (Man8B) (8, 9) acts as a signal triggering ERAD of glycoproteins (1012). Disruption of the ER {alpha}-mannosidase gene in yeast (10, 11) and inhibition of ER ManI in mammalian cells (13, 14) both prevent ERAD. We recently reported the molecular cloning of mouse EDEM (ER degradation enhancing {alpha}-mannosidase-like protein) and its involvement in glycoprotein ERAD. It was suggested that EDEM is a putative lectin, which most likely binds Man8B on misfolded {alpha}1-antitrypsin and accelerates its degradation (15). Two groups also reported the yeast homolog of EDEM and its function in yeast ERAD (16, 17), indicating that the ERAD mechanisms involved in the degradation of misfolded glycoproteins are similar in yeast and mammals. Both ER ManI and EDEM are ER resident transmembrane proteins containing characteristic signature motifs of class I {alpha}1,2-mannosidases (glycosylhydrolase family 47). Despite this significant sequence similarity, EDEM lacks {alpha}1,2-mannosidase activity with Man9GlcNAc as substrate (15). In addition, these two proteins differ in their response to ER stress. EDEM is induced by various forms of ER stress, but ER ManI is not (15).

In this report, we show that overexpression of human ER ManI accelerates the degradation of the terminally misfolded {alpha}1-antitrypsin genetic variant-null Hong Kong (A1AT NHK) (18). We also show the combined effects of ER ManI and EDEM on the degradation of misfolded {alpha}1-antitrypsin. Glycan analysis on misfolded NHK shows that overexpression of ER ManI greatly increases the formation of Man8GlcNAc2 and Glc1Man8GlcNAc2 and also stimulates trimming of N-linked oligosaccharides to Man5GlcNAc2 in vivo. These experiments suggest that the misfolded glycoprotein interacts both with ER ManI and EDEM before being recognized by downstream ERAD components.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture and Transfection—Human HEK 293 cells were cultured in DMEM supplemented with 10% fetal bovine serum, and transfection of plasmids encoding human ER ManI, mouse EDEM, and human {alpha}1-antitrypsin-null Hong Kong were performed using FuGENE 6 transfection reagents (Roche Molecular Biochemicals) according to the protocol recommended by the manufacturer. Approximately 1.5 x 105 cells were plated on poly-L-lysine-coated 3.5-cm dishes. After 24 h of plating, 0.5 µg of plasmid encoding ER ManI, EDEM, or pMH vector were mixed with 1 µg of plasmid encoding the {alpha}1-antitrypsin variant A1AT NHK for transfection, and cells were pulse-labeled and harvested 36 h post-transfection.

Reagents—Kifunensine, an inhibitor of ER ManI, was kindly provided by Fujisawa Pharmaceutical Co. (Osaka, Japan) and added to the culture medium at a concentration of 5 µg/ml for 4 h prior to pulse-labeling. The proteasome inhibitor lactacystin was purchased from Kyowa Medics Co. (Tokyo, Japan) and added to the culture medium at a concentration of 1 mM for 4 h prior to pulse-labeling. The inhibitors were also present in the medium during the pulse and the chase periods.

Plasmid Construction—Human ER ManI cDNA was subcloned into the pMH vector (Roche Molecular Biochemicals) by PCR. The entire open reading frame (9) was amplified from cDNA using a sense primer containing a HindIII site and a Kozak sequence (5'-AAAAAAGCTTCCACCATGGCTGCCTGCGAGGGCAGGAG-3') and an antisense primer containing a NotI site and omitting the stop codon (5'-AAAAAAAAGCGGCCGCGCTGCAGGGGTCCAGATAGGCAGAG-3'). The open reading frame amplicon was digested with HindIII and NotI and cloned into the HindIII/NotI sites of pMH in-frame with the C-terminal HA-tag. Mouse EDEM cDNA was tagged with HA at its C terminus in pCMV-SPORT2 vector (Invitrogen) as described previously (15). The NHK variant was constructed as described elsewhere (15).

Metabolic Labeling and Immunoprecipitation—Cells were preincubated in DMEM lacking methionine (Invitrogen) for 30 min and labeled with Expre35S35S protein labeling mixture (PerkinElmer Life Sciences) for 15 min at a concentration of 8.2 MBq/ml. The cells were then incubated in DMEM during the chase period. After washing twice with phosphate-buffered saline lacking Ca2+ and Mg2+, cells were incubated on ice for 20 min in lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, supplemented with protease inhibitors) (15). For immunoprecipitation, Nonidet P-40 soluble cell lysates were mixed with various antibodies (1/50 dilution), and the immune complexes were collected using either Protein A- or Protein G-Sepharose beads (Amersham-Pharmacia, Amersham, UK) (19). One-half of the cell lysate was used for immunoprecipitation using antibody against A1AT, and the other half was incubated with anti-HA antibody. In cells co-transfected with NHK and ER ManI or EDEM, the radioactivity of immunoprecipitated NHK decreased compared with cells transfected with NHK and pMH. To obtain approximately equal signals for the immunoprecipitated NHK at chase 0 h, the gels were exposed 2 or 3 times longer for samples co-transfected with ER ManI or EDEM than for those co-transfected with pMH. Alternatively in some experiments, one-half or one-third of the cell lysates was used for immunoprecipitation in pMH transfected cells in comparison with ER ManI or EDEM transfected cells. The conditions are indicated in the figure legends. The immune complex was boiled in Laemmli's sample buffer containing 0.1 M dithiothreitol and separated by 10% SDS-PAGE, unless otherwise indicated in the legends. Radioactivity was quantified by exposing the gels to a PhosphorImager (Storm, Amersham Biosciences), and the gels were exposed to x-ray films (HR-HA, Fuji Photo Film Co. Ltd., Japan) afterward.

For labeling with [3H]mannose, cells were preincubated in DMEM containing 1 mM glucose (Invitrogen) for 30 min and labeled with 7.4 MBq/ml D-[2-3H]mannose for 1 h. Cells were then chased for the times indicated in DMEM containing 25 mM glucose (Invitrogen) supplemented with 5 mM mannose (20). Cell lysis, immunoprecipitation, and SDS-PAGE were performed as described for the labeling with 35S-protein-labeling mixture, and the samples were blotted onto a PVDF membrane (Bio-Rad) in 5 mM sodium tetraborate buffer. The position of the [3H]mannose-labeled NHK bands on the PVDF membrane were identified by exposing the membrane to a PhosphorImager.

Antibodies—Antiserum against {alpha}1-antitrypsin was purchased from Cappel (ICN Pharmaceuticals, Inc.), and purified IgG against the HA-tag was obtained from Santa Cruz Biotechnology, Inc. Human ER ManI antibody was prepared by immunizing rabbits with a keyhole limpet hemocyanin-conjugated synthetic peptide (GRRDVEVKPADRHNLLRPET). The antiserum was affinity-purified using the peptide. For the antibody against mouse EDEM, multiple antigenic peptide was synthesized using the following peptide sequence, DERRYSLPLKSIYMRQID. Whole rabbit serum was used for the experiments.

Western Blotting—Nonidet P-40-soluble cell lysates or immunoprecipitates prepared as described above (see "Metabolic Labeling and Immunoprecipitation") were adjusted to 1 x Laemmli's buffer containing 0.1 M dithiothreitol and separated by 10% SDS-PAGE. For Western blotting, 40 µg of protein was loaded per lane. For Western blotting following immunoprecipitation, 400 µg of protein of Nonidet P-40-soluble cell lysate was used as starting material. After blotting to a nitrocellulose membrane, antigen-antibody complexes were detected by ECL (Amersham Biosciences) and exposed to x-ray films.

Characterization of Oligosaccharides—The [3H]mannose-labeled NHK bands on the PVDF membranes were cut into small pieces. The pieces were first rinsed with methanol and then with 0.1 M sodium citrate, pH 5.5, three times for 15 min at 37 °C, and the washes were discarded. The membrane pieces were then incubated with Endo-H (New England Biolabs) in the same buffer at 37 °C for 48 h. Endo-H (1000 units) was added at 0, 12 and 36 h of incubation, and the membrane pieces were washed three times with water. The extracts and washes were combined, boiled for 3 min, and lyophilized. The labeled oligosaccharides completely released by this procedure were dissolved in water, mixed with standard 14C-labeled Glc3Man9GlcNAc and fractionated by HPLC as described previously (21). In some cases, an internal standard of 14C-labeled Glc1Man8GlcNAc was also used. It was prepared by treatment of labeled Glc1Man9GlcNAc for 45 min at 37 °C with 0.2 mg of purified recombinant {alpha}1,2-mannosidase of Saccharomyces cerevisiae (22).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Enhanced Degradation of A1AT NHK by Overexpression of ER ManI—To examine the effect of ER mannosidase I on ERAD of misfolded glycoproteins, human ER ManI cDNA was transfected into HEK 293 cells along with the A1AT NHK. A1AT is a serum protein belonging to a serine protease inhibitor superfamily. Mutations in {alpha}1-antitrypsin cause emphysema or liver cirrhosis (23). The NHK genetic variant of A1AT misfolds terminally in the ER and is degraded by ERAD (12, 15). Transfection of human ER ManI greatly enhanced the degradation of misfolded A1AT NHK in comparison with mock transfected cells (Fig. 1A, closed arrow, compare lanes 1–3 with lanes 4–6). NHK was not secreted into the medium of cells co-transfected with ER ManI (data not shown) nor of cells co-transfected with vector alone (15, 24). Quantitative analysis revealed that the t1/2 of transfected NHK in 293 cells was ~100 min. Co-transfection of ER ManI shortened the t1/2 of NHK to about 50 min (Fig. 1C).



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 1.
Transient transfection of ER ManI enhances the degradation of A1AT NHK variant in 293 cells. 293 cells transfected with plasmids encoding A1AT NHK and either ER ManI (+) or the pMH vector (-) were labeled with EXPRE35S35S protein-labeling mixture for 15 min and chased for the times indicated. The closed arrow indicates the position of A1AT NHK, and the open arrows show that of ER ManI. Molecular weight marker positions are noted on the left. A, autoradiogram of SDS-PAGE of the immunoprecipitates using anti-A1AT antibody (Ab). Because the radioactivity of NHK co-transfected with ER ManI at 0 h chase was always weaker than that from cells co-transfected with the vector (pMH), lanes 4–6 were exposed twice as long as lanes 1–3. B, autoradiogram of the immunoprecipitates from the same samples as in A, except using anti-HA antibody. The open arrowhead indicates proteins that were co-immunoprecipitated with transfected ER ManI. C, quantitative analysis of the NHK degradation. The rate of NHK degradation in cell lysates is plotted on a semi-log graph. The data shown are the means with standard deviations of five independent experiments. Radioactivity was quantified using a PhosphorImager. The value at 0 h chase was set arbitrarily to 1.0 in both mock and ER ManI transfected cells.

 

NHK immunoprecipitated from cell lysates transfected with ER ManI migrated slightly faster on SDS-PAGE than that from mock transfected cells (Fig. 1A, closed arrow). Kifunensine inhibited the degradation of NHK in cells co-transfected with ER ManI (Fig. 2, A and C) and also resulted in a small decrease in NHK electrophoretic mobility, consistent with inhibition of ER {alpha}1,2-mannosidase activity (Fig. 2A, black arrow, compare lanes 1–3 with lanes 4–6). Therefore overexpression of ER ManI enhances ERAD of misfolded NHK by accelerating mannose trimming from its N-linked glycans. This conclusion was further supported by NHK oligosaccharide analyses described below.



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 2.
Kifunensine inhibits the degradation of NHK in ER ManI transfected cells. Kifunensine (5 µg/ml) was added to the culture medium 4 h prior to metabolic labeling and was present in the medium during the pulse-labeling and chase period. Both NHK and ER ManI were transfected in all the cells. Immunoprecipitates were prepared as in Fig. 1. Arrow notations are as described in Fig. 1. A and B, autoradiogram of the immunoprecipitates using antibody (Ab) against A1AT (A) and HA-tag (B), respectively. C, quantification of NHK within the cell. The radioactivity of NHK at 0 h chase was set arbitrarily to 1.0, and the means with standard deviations of three independent experiments were shown.

 

Co-immunoprecipitation of ER ManI with NHK was detected in cells transfected with ER ManI (Fig. 1A, open arrow). Notably, the transfected ER ManI was degraded very rapidly (Fig. 1B, lanes 4–6, and see below). A broad uncharacterized protein band of ~170 kDa was co-immunoprecipitated with ER ManI using anti-HA antibody (Fig. 1B, lanes 4–6). This 170-kDa band decreased in parallel with the HA-tagged ER ManI during chase.

The degradation of co-transfected ER ManI was not inhibited by the addition of kifunensine (Fig. 2B, compare lanes 1–3 with lanes 4–6), in accordance with the fact that human ER ManI is not a glycoprotein (8, 9). Kifunensine also decreased the mobility of the 170-kDa co-immunoprecipitated protein band (Fig. 2B, compare lanes 1 and 4), suggesting that the 170-kDa band is glycosylated.

Inhibition of NHK Degradation by Lactacystin—The effect of the proteasome inhibitor lactacystin on NHK degradation was then examined. The accelerated degradation of NHK in cells transfected with ER ManI was repressed by lactacystin (Fig. 3A, arrow, compare lanes 1–3 with lanes 4–6), indicating that the enhanced NHK degradation induced by ER ManI overexpression occurs through the ERAD pathway. Again, it is notable that the transfected ER ManI is rapidly degraded (Fig. 3B, lanes 1–3, open arrow, see also Figs. 1B and 2B). General protein synthesis examined by the incorporation of [35S]methionine into the trichloroacetic acid-insoluble fraction was not inhibited by transfection of ER ManI. The degradation of ER ManI is independent of proteasomes (Fig. 3B, compare lanes 1–3 with lanes 4–6). The degradation of ER ManI was not inhibited by other protease inhibitors including serine or cysteine protease inhibitors, calpain inhibitor, nor aspartic protease inhibitor.2



View larger version (68K):
[in this window]
[in a new window]
 
FIG. 3.
Lactacystin inhibits the degradation of NHK in ER ManI transfected cells. Cells were transfected with ER ManI and NHK and treated with or without lactacystin (1 mM) for 4 h prior to metabolic labeling. In lactacystin + cells, drug was present during pulse labeling and during chase. Autoradiogram of SDS-PAGE of immunoprecipitates are shown with anti-A1AT antibody (Ab) (A) or with anti-HA-tag antibody (B). Arrows and an arrowhead indicate the same species as in Fig. 1.

 

Combined Effects of ER ManI and EDEM on NHK Degradation—Recently, we reported that mouse EDEM, which has sequence homology to {alpha}1,2-mannosidases but lacks enzyme activity with Man9GlcNAc as substrate, accelerates ERAD of misfolded NHK when transfected into 293 cells (15). EDEM was shown to interact with NHK in co-immunoprecipitation experiments and was postulated to recognize misfolded glycoproteins to sort them for retrotranslocation. We first compared the effects of transfection with ER ManI and with EDEM on ERAD of NHK. ER ManI and EDEM expressed individually shortened the intracellular half-life of NHK (Fig. 4A, closed arrow, compare lanes 1–3 with lanes 4–6 or 7–9). Co-immunoprecipitation of either ER ManI or EDEM was detected with NHK, using antibody raised against A1AT (Fig. 4A, lanes 4–6, open arrow showing ER ManI; lanes 7–9, thin arrow indicating EDEM). In the immunoprecipitates using anti-HA antibody, protein bands of ~170 and 150 kDa on SDS-PAGE were observed in ER ManI and EDEM transfected cells, respectively (Fig. 4B, lanes 4–6, open arrowhead for ER ManI; lanes 7–9, closed arrowhead for EDEM). Although transfected ER ManI is rapidly degraded, transfected EDEM is stable during the 2-h chase period (Fig. 4B, compare lanes 4–6 with lanes 7–9).



View larger version (37K):
[in this window]
[in a new window]
 
FIG. 4.
Comparison of the effects of ER ManI and EDEM on NHK degradation. Cells were transfected with pMH (vector), ER ManI, or EDEM, and immune complexes with anti-A1AT antibody (Ab) (A) and anti-HA antibody (B) were separated by SDS-PAGE. To obtain nearly equal amounts of NHK radioactivity at chase 0 h in all the transfectants, 3 and 2 volumes of cell lysate were used for immunoprecipitation in ER ManI and EDEM transfected cells to that of mock transfected cells, respectively. Open arrows indicate the position of ER ManI, and thin arrows show that of EDEM. Open and closed arrowheads indicate the bands that co-immunoprecipitated with ER ManI and EDEM, respectively. Closed arrow indicates the position of NHK. C, immunoprecipitates with anti-A1AT antibody prepared at each chase period were separated in adjacent lanes on SDS-PAGE. Three and two volumes of cell lysate were used for immunoprecipitation in ER ManI and EDEM transfected cells compared with that of mock transfected cells, respectively.

 

Co-transfection of 293 cells with both ER ManI and EDEM further enhanced ERAD of NHK, compared with ER ManI alone, showing that there is a combined effect of these two ER resident proteins on NHK degradation (Fig. 5A, compare lanes 1–3 with lanes 4–6). Enhancement of degradation of NHK was also evident in cells co-transfected with both ER ManI and EDEM compared with EDEM alone (Fig. 5A, compare lanes 4–6 with lanes 7–9). Because of the rapid degradation of NHK observed following transfection of both ER ManI and EDEM in this experiment, cell lysates were examined at shorter chase periods. The levels of expression of ER ManI, EDEM, and NHK were reduced when both ER membrane proteins and substrate proteins were co-transfected. However, when the proteasome inhibitor lactacystin was added, similar amounts of labeled NHK were recovered from the immunoprecipitates of cell lysates (Fig. 5B, lanes 3, 4, 7, and 8), whereas only a very small amount of NHK was detected in cells overexpressing both ER ManI and EDEM after a 45-min chase in the absence of lactacystin (Fig. 5B, lane 6). These results confirm that the reduced amount of labeled NHK immunoprecipitated from cells co-transfected with ER ManI and EDEM was actually due to degradation by the proteasomes and not due to reduced synthesis of NHK.



View larger version (22K):
[in this window]
[in a new window]
 
FIG. 5.
Combined effects of ER ManI and EDEM on NHK degradation. NHK degradation in cells co-expressing EDEM in addition to ER ManI. Equal amounts of cell lysates were used for immunoprecipitation of all the samples. A, cells were pulse-labeled for 15 min and chased for the periods indicated. For lanes 4–6, the film was exposed twice as long. The result of one representative experiment is shown, and the relative radioactivity of the NHK is indicated below each lane (radioactivity at chase 0 h of each transfection was arbitrarily set to 1.0). B, cells were pulse-labeled for 15 min (P) and chased for 45 min (C) with or without lactacystin. Specific immunoprecipitates using anti-A1AT antibody are shown, and the relative radioactivity was indicated below each lane (radioactivity of lane 1 was arbitrarily set to 1.0).

 

We then investigated whether ER ManI and EDEM form a complex with each other. We prepared antisera against synthetic peptides from both ER ManI and EDEM. Each anti-serum recognized its corresponding overexpressed protein by immunoprecipitation and Western blot analysis but hardly detected endogenous levels of the proteins. Accordingly, we co-transfected HA-tagged ER ManI with untagged EDEM or untagged ER ManI with HA-tagged EDEM. We performed immunoprecipitation of labeled cell lysates, as well as immunoprecipitation of cell lysates followed by Western blotting using either HA-tag or synthetic peptide antibodies. We did not detect any interaction of overexpressed ER ManI with EDEM (data not shown). The co-immunoprecipitated band observed in cells transfected with ER ManI was consistently larger than that observed in EDEM transfected cells (Fig. 4B, lanes 4–9, open and closed arrowheads), indicating that the proteins differ.

Characterization of Oligosaccharides on NHK—To determine the structure of the oligosaccharides present on NHK, cells were labeled with [2-3H]mannose, and the oligosaccharides released by Endo-H from immunoprecipitated NHK were analyzed by HPLC (Fig. 6). In mock transfected cells the major labeled oligosaccharides on NHK were Glc1Man9GlcNAc and Man9GlcNAc following pulse-labeling, along with smaller amounts of Man8GlcNAc (Fig. 6A). The identity of the oligosaccharides was confirmed by exhaustive treatment with jack bean {alpha}1,2-mannosidase followed by HPLC of the products. Glc1Man9GlcNAc yielded about 47% labeled Glc1Man4GlcNAc and mannose whereas Man9GlcNAc was entirely converted to mannose (data not shown). With increasing times of chase, trimming of NHK glycans to Man7GlcNAc, Man6GlcNAc (Fig. 6, B and C), and even to Man5GlcNAc after 4 h of chase (data not shown) was observed. Therefore, the oligosaccharides on misfolded NHK are trimmed beyond Man8GlcNAc2 by endogenous {alpha}1,2-mannosidase activity.



View larger version (37K):
[in this window]
[in a new window]
 
FIG. 6.
Oligosaccharides on misfolded NHK transfected into 293 cells. 293 cells transfected with A1AT NHK and either the pMH vector (A–C), ER ManI (D–F), or EDEM (G–I) were metabolically labeled with [3H]mannose for 1 h and chased for 0 h (A, D, G), 1 h (B, E, H), or 2 h (C, F, I). Following immunoprecipitation using anti-A1AT antibody, samples were separated by 10% SDS-PAGE and were blotted onto a PVDF membrane. The oligosaccharides released from NHK by Endo-H were fractionated by HPLC. Arrows indicate the position of the Glc3Man9GlcNAc internal standard, M5–M9 show 3H-labeled Man5–9GlcNAc, G1M8 corresponds to Glc1Man8GlcNAc (shown in Fig. 7), and G1M9, which co-eluted with 14C-labeled Glc1Man9GlcNAc (not shown), corresponds to Glc1Man9GlcNAc.

 



View larger version (22K):
[in this window]
[in a new window]
 
FIG. 7.
Co-chromatography of oligosaccharides with Glc1Man8GlcNAc standard. 293 cells transfected with A1AT NHK and either ER Man I (A) or EDEM (B) were metabolically labeled with [3H]mannose for 1 h, chased for 2 h, and then analyzed, as described in Fig. 6. The arrow indicates the position of the Glc3Man9GlcNAc internal standard, and the dotted line indicates the position of 14C-labeled Glc1Man8GlcNAc internal standard.

 
Overexpression of ER ManI caused a large increase in Man8GlcNAc, and an appearance of Glc1Man8GlcNAc (Fig. 6, D, E, and F, and Fig. 7A). At the same time, there was a large decrease in the proportion of Glc1Man9GlcNAc and Man9GlcNAc2 as well as an increase in Man5–7GlcNAc compared with mock transfected cells. An aliquot of the sample from Fig. 6F subjected to HPLC with an internal standard of Glc1Man8GlcNAc (Fig. 7A) confirmed the identity of the large peak of Glc1Man8GlcNAc and the disappearance of Man9GlcNAc in cells transfected with ER ManI compared with mock transfected cells. The Glc1Man8GlcNAc may have been formed by the action of ER ManI on Glc1Man9GlcNAc or by the addition of glucose to the increased Man8GlcNAc by UDP-glucose:glycoprotein glucosyltransferase. These results show that ER ManI is capable of trimming beyond Man8GlcNAc2 in vivo as was recently reported for recombinant ER ManI in vitro (25). In cells overexpressing EDEM the major labeled oligosaccharides were Glc1Man9GlcNAc and Man9GlcNAc, as in mock transfected cells with smaller proportions of Man6–8GlcNAc (Fig. 6, G, H, and I). When a sample similar to that shown in Fig. 6I was fractionated in the presence of the Glc1 Man8GlcNAc internal standard (Fig. 7B), Man9GlcNAc and a small amount of Glc1Man8GlcNAc were found. When cells were treated with kifunensine the formation of Man6–8GlcNAc was nearly completely inhibited (Fig. 8B) showing that ER {alpha}1,2-mannosidase II is not responsible for trimming NHK oligosaccharides in vivo.



View larger version (17K):
[in this window]
[in a new window]
 
FIG. 8.
Effect of kifunensine on the oligosaccharides of misfolded NHK. Cells were transfected with NHK and analyzed as described in Fig. 6. Cells were harvested after a 3-h chase. The cells were preincubated in either the absence (A) or the presence (B) of 5 µg/ml kifunensine for 4 h prior to metabolic labeling with [3H]mannose. The size of the oligosaccharides is indicated as in Fig. 6.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In the present study, we have shown that overexpression of human ER ManI in HEK 293 cells enhances ERAD of the terminally misfolded glycoprotein NHK. Accelerated degradation of NHK in cells overexpressing ER ManI was inhibited by lactacystin and by kifunensine, indicating that misfolded NHK was degraded through the ERAD pathway and that overexpression of ER ManI enhanced ERAD by accelerating trimming of its N-glycans. It has been postulated that the processing of N-linked oligosaccharides to Man8B by ER ManI acts as a signal for degradation of misfolded glycoproteins (1, 7, 13, 14). However, all studies to date were based on the assumption that Man8B is the only oligosaccharide found on misfolded glycoproteins due to ER ManI activity and on observations of carbohydrate trimming from misfolded glycoproteins by shifts in their mobility upon SDS-PAGE. In this first study reporting HPLC analysis of the glycans on terminally misfolded NHK, the results clearly show that a mixture of oligosaccharides is found on NHK and that the accepted assumption that only Man8B is formed by ER ManI needs to be revised.

In mock transfected cells, Glc1Man9GlcNAc, Man9GlcNAc, and Man8GlcNAc were the major oligosaccharides found on NHK, but smaller amounts of Man7GlcNAc and Man6GlcNAc were also present. It is therefore possible that oligosaccharides other than Man8B, or in addition to Man8B, may act as recognition markers for ERAD. The relatively small amounts of Man7GlcNAc and Man6GlcNAc found on NHK might be the result of selective ERAD of specific NHK glycoforms bearing these oligosaccharides. The presence of Glc1Man9GlcNAc on NHK is consistent with previous studies demonstrating NHK association with calnexin (26). The results also show that the additional trimming beyond Man8GlcNAc is not due to ER {alpha}-mannosidase II because it was sensitive to kifunensine (Fig. 8).

Overexpression of ER ManI, which increased ERAD of NHK, also greatly stimulated trimming of mannose residues to Man5GlcNAc, Man6GlcNAc, Man7GlcNAc, and Man8GlcNAc, as well as the formation of Glc1Man8GlcNAc. With the exception of the latter, the same oligosaccharides were formed in mock transfected cells, showing that the stimulation of NHK degradation caused by overexpression of ER ManI is not likely caused by the formation of atypical glycans. The increased trimming of N-glycans beyond Man8GlcNAc observed in cells overexpressing ER ManI is consistent with previous experiments with recombinant ER ManI in vitro indicating that ER ManI is less specific than previously believed (25).

The pattern of oligosaccharides found in EDEM and mock transfected cells is very similar, but there is always a shoulder ahead of the Man9GlcNAc peak that corresponds to a small amount of Glc1Man8GlcNAc, suggesting that EDEM somehow facilitates either trimming of Glc1Man9GlcNAc to Glc1 Man8GlcNAc or glucosylation of Man8GlcNAc by UDP-glucose: glycoprotein glucosyltransferase.

We demonstrated combined effects of ER ManI and of EDEM on ERAD. We previously reported that EDEM interacts with and accelerates the degradation of misfolded NHK, suggesting that EDEM may be a putative lectin, which recognizes misfolded glycoproteins for ERAD (15). NHK degradation is faster in cells co-transfected with both ER ManI and EDEM than in cells transfected with ER ManI or EDEM alone (Fig. 5A).

We also obtained evidence indicating that ER ManI and EDEM are part of different complexes because different proteins were co-immunoprecipitated with each of them, and no evidence that ER ManI and EDEM form a complex with each other was obtained. We propose a model whereby misfolded glycoproteins are recognized independently by ER ManI and by EDEM. The identities of the proteins co-immunoprecipitated with ER ManI and EDEM remain to be determined, which may aid in the elucidation of productive glycoprotein folding and in understanding the machinery leading to retrotranslocation and subsequent degradation by proteasomes.

Notably, ER ManI transfected into 293 cells was degraded very rapidly through a mechanism independent of cytoplasmic proteasomes (Fig. 3B, lanes 1–6). Despite its rapid turnover, we could detect the expression of transfected ER ManI by Western blot analysis using antibody against HA-tag or human ER ManI peptide. The level of expression of ER ManI in transfected cells is higher than that of endogenous ER ManI because we could not detect the latter by Western blot analysis using anti-peptide antibody. Although the molecular mechanism and the reason for the rapid degradation of ER ManI will require further investigation, the results suggest that the level of ER ManI expression is stringently controlled.


    FOOTNOTES
 
* This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to N. H., I. W., and K. N.) and by a grant from the Canadian Institutes of Health Research (to A. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger}{ddagger} Present address: Dept. of Cell Science, Institute of Biomedical Sciences, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan. Back

To whom correspondence should be addressed. Tel.: 81-75-751-3849; Fax: 81-75-751-4646; E-mail: nobuko{at}frontier.kyoto-u.ac.jp.

1 The abbreviations used are: ER, endoplasmic reticulum; ERAD, ER-associated degradation; A1AT NHK, {alpha}1-antitrypsin-null Hong Kong; ER ManI, ER {alpha}1,2-mannosidase I; EDEM, ER degradation enhancing {alpha}-mannosidase-like protein; Man8B, Man8GlcNAc2 isomer B; HEK 293, human embryonic kidney 293; Endo-H, endo-{beta}-N-acetylglucosaminidase H; DMEM, Dulbecco's modified Eagle's medium; HA, hemagglutinin; PVDF, polyvinylidene difluoride. Back

2 N. Hosokawa, I. Wada, and K. Nagata, unpublished observation. Back


    ACKNOWLEDGMENTS
 
We thank Björn Stork for assistance in construct preparation and Dr. Pedro Romero for comments on the manuscript.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ellgaard, L., Molinari, M., and Helenius, A. (1999) Science 286, 1882-1888[Abstract/Free Full Text]
  2. Herscovics, A. (1999) Biochim. Biophys. Acta 1473, 96-107[Medline] [Order article via Infotrieve]
  3. Parodi, A. J. (2000) Annu. Rev. Biochem. 69, 69-93[CrossRef][Medline] [Order article via Infotrieve]
  4. Helenius, A., and Aebi, M. (2001) Science 291, 2364-2369[Abstract/Free Full Text]
  5. Bonifacino, J. S., and Weissman, A. M. (1998) Annu. Rev. Cell Dev. Biol. 14, 19-57[CrossRef][Medline] [Order article via Infotrieve]
  6. Plemper, R. K., and Wolf, D. H. (1999) Trends Biochem. Sci. 24, 266-270[CrossRef][Medline] [Order article via Infotrieve]
  7. Cabral, C. M., Liu, Y., and Sifers, R. (2001) Trends Biochem. Sci. 26, 619-624[CrossRef][Medline] [Order article via Infotrieve]
  8. Gonzalez, D. S., Karaveg, K., Vandersall-Nairn, A. S., Lal, A., and Moremen, K. W. (1999) J. Biol. Chem. 274, 21375-21386[Abstract/Free Full Text]
  9. Tremblay, L. O., and Herscovics, A. (1999) Glycobiology 9, 1073-1078[Abstract/Free Full Text]
  10. Knop, M., Hauser, N., and Wolf, D. H. (1996) Yeast 12, 1229-1238[CrossRef][Medline] [Order article via Infotrieve]
  11. Jakob, C. A., Burda, P., Roth J., and Aebi, M. (1998) J. Cell Biol. 142, 1223-1233[Abstract/Free Full Text]
  12. Liu, Y., Choudhury, P., Cabral, C. M., and Sifers, R. N. (1999) J. Biol. Chem. 274, 5861-5867[Abstract/Free Full Text]
  13. Tokunaga, F., Brostrom C., Koide, T., and Arvan, P. (2000) J. Biol. Chem. 275, 40757-40764[Abstract/Free Full Text]
  14. Fagioli, C., and Sitia, R. (2001) J. Biol. Chem. 276, 12885-12892[Abstract/Free Full Text]
  15. Hosokawa, N., Wada, I., Hasegawa, K., Yorihuzi, T., Tremblay, L. O., Herscovics, A., and Nagata, K. (2001) EMBO Rep. 2, 415-422[Abstract/Free Full Text]
  16. Jakob, C. A., Bodmer, D., Spirig, U., Bättig, P., Marcil, A., Dignard, D., Bergeron, J. J. M., Thomas, D. Y., and Aebi, M. (2001) EMBO Rep. 2, 423-430[Abstract/Free Full Text]
  17. Nakatsukasa, K., Nishikawa, S.-I., Hosokawa, N., Nagata, K., and Endo, T. (2001) J. Biol. Chem. 276, 8635-8638[Abstract/Free Full Text]
  18. Sifers, R. N., Brashears-Macatee, S., Kidd, V. J., Muensch, H., and Woo, S. L. C. (1988) J. Biol. Chem. 263, 7330-7335[Abstract/Free Full Text]
  19. Satoh, M., Hirayoshi, K, Yokota, S-i., Hosokawa, N., and Nagata, K. (1996) J. Cell Biol. 133, 469-483[Abstract]
  20. Moore, S. E. H., and Spiro, R. G. (1994) J. Biol. Chem. 269, 12715-12721[Abstract/Free Full Text]
  21. Romero, P. A., Saunier, B., and Herscovics, A. (1985) Biochem. J. 226, 733-740[Medline] [Order article via Infotrieve]
  22. Lipari, F., and Herscovics, A. (1999) Biochemistry 38, 1111-1118[CrossRef][Medline] [Order article via Infotrieve]
  23. Cox, D. W. (1995) In Scriver, C. B., Beaudet, A. L., Sly, W. S., and Valle, D. (eds) Metabolic Basis of Inherited Disease, pp. 4125-4158, McGraw-Hill Inc., New York
  24. Liu, Y., Choudhury, P., Cabral, C, M., and Sifers, R. N. (1997) J. Biol. Chem. 272, 7946-7951[Abstract/Free Full Text]
  25. Herscovics, A., Romero, P. A., and Tremblay, L. O. (2002) Glycobiology 12, 14G-15G[Medline] [Order article via Infotrieve]
  26. Le, A., Steiner, J. L., Ferrell, G. A., Shaker, J. C., and Sifers, R. N. (1994) J. Biol. Chem. 269, 7514-7519[Abstract/Free Full Text]